USSTOCK.TODAY
Market Closed
Log in Sign up

Prelude Therapeutics to Collaborate with Eli Lilly on Phase 1 Breast Cancer Treatment Trial

Nasdaq +1 ·

PRLD
PRLD Prelude Therapeutics Inc
$3.56 -4.81%
View chart & analysis →
LLY -1.36%
  1. 1Prelude Therapeutics announced a collaboration and supply agreement with Eli Lilly for the Phase 1 clinical trial of the investigational breast cancer treatment PRT13722.
  2. 2The FDA has approved the Investigational New Drug (IND) application to allow Prelude Therapeutics to proceed with the clinical study.
  3. 3Prelude Therapeutics expects to begin patient enrollment in the fourth quarter of 2026.

So what's the key point?

Prelude Therapeutics has decided to test a breast cancer treatment together with Eli Lilly. The study is expected to move forward with patient enrollment starting in the fourth quarter of 2026.

Source Nasdaq +1 · View original ↗

Related 3-line summaries

Three stocks that doubled their dividends over the past five years Nasdaq +1 · 47m agoEli Lilly Stock Split Possibility and Corporate Status Nasdaq +2 · 19h agoEli Lilly Announces Phase 3b Clinical Results for Taltz and Zepbound Combination Therapy Clinical Trials Arena +3 · yesterday
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news